Eli Lilly shares jump as blowout earnings, obesity drug demand fuel profit upgrade

Core Insights - Eli Lilly's shares increased nearly 4% in premarket trading following the release of third-quarter earnings that surpassed expectations and an upward revision of its annual profit forecast [1] Financial Performance - The pharmaceutical company reported third-quarter earnings that exceeded market expectations [1] - Eli Lilly raised its annual profit forecast, indicating strong financial performance and positive outlook for the remainder of the year [1]